Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection

Cerium oxide nanoparticles (nanoceria) possess catalytic and regenerative radical scavenging activities. The ability of nanoceria to maintain cellular redox balance makes them ideal candidates for treatment of retinal diseases whose development is tightly associated with oxidative damage. We have de...

Full description

Saved in:
Bibliographic Details
Published inPloS one Vol. 8; no. 3; p. e58431
Main Authors Wong, Lily L, Hirst, Suzanne M, Pye, Quentin N, Reilly, Christopher M, Seal, Sudipta, McGinnis, James F
Format Journal Article
LanguageEnglish
Published United States Public Library of Science 11.03.2013
Public Library of Science (PLoS)
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Cerium oxide nanoparticles (nanoceria) possess catalytic and regenerative radical scavenging activities. The ability of nanoceria to maintain cellular redox balance makes them ideal candidates for treatment of retinal diseases whose development is tightly associated with oxidative damage. We have demonstrated that our stable water-dispersed nanoceria delay photoreceptor cell degeneration in rodent models and prevent pathological retinal neovascularization in vldlr mutant mice. The objectives of the current study were to determine the temporal and spatial distributions of nanoceria after a single intravitreal injection, and to determine if nanoceria had any toxic effects in healthy rat retinas. Using inductively-coupled plasma mass spectrometry (ICP-MS), we discovered that nanoceria were rapidly taken up by the retina and were preferentially retained in this tissue even after 120 days. We also did not observe any acute or long-term negative effects of nanoceria on retinal function or cytoarchitecture even after this long-term exposure. Because nanoceria are effective at low dosages, nontoxic and are retained in the retina for extended periods, we conclude that nanoceria are promising ophthalmic therapeutics for treating retinal diseases known to involve oxidative stress in their pathogeneses.
Bibliography:Conceived and designed the experiments: LLW JFM SS CMR. Performed the experiments: LLW SMH QNP CMR. Analyzed the data: LLW SMH QNP JFM CMR SS. Contributed reagents/materials/analysis tools: LLW CMR SS JFM. Wrote the paper: LLW SMH QNP JFM CMR SS.
Competing Interests: LLW, SS, and JFM are co-inventors of US Patents: 7727559 and 7347987, European Patent: 1879570, and Australian Patent: 2006242541. SS is a co-inventer of US Patent: 7504356. JFM is Chief Scientist of a startup company, Nantiox, which is licensed to use nanoceria to destroy reactive oxygen species but no corporate funding was used to support this research. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0058431